|
Index | - | P/E | - | EPS (ttm) | - | Insider Own | 12.70% | Shs Outstand | 8.37M | Perf Week | -10.73% |
Market Cap | 20.85M | Forward P/E | - | EPS next Y | - | Insider Trans | 0.00% | Shs Float | 6.22M | Perf Month | 45.62% |
Income | - | PEG | - | EPS next Q | - | Inst Own | 0.80% | Short Float / Ratio | 0.73% / 0.03 | Perf Quarter | -11.41% |
Sales | 0.00M | P/S | 8487.38 | EPS this Y | 13.00% | Inst Trans | - | Short Interest | 0.05M | Perf Half Y | - |
Book/sh | 1.51 | P/B | 1.54 | EPS next Y | - | ROA | - | Target Price | - | Perf Year | - |
Cash/sh | 1.51 | P/C | 1.54 | EPS next 5Y | - | ROE | - | 52W Range | 1.31 - 15.55 | Perf YTD | 45.62% |
Dividend | - | P/FCF | - | EPS past 5Y | - | ROI | - | 52W High | -85.02% | Beta | - |
Dividend % | - | Quick Ratio | 9.60 | Sales past 5Y | - | Gross Margin | - | 52W Low | 77.86% | ATR | 0.36 |
Employees | 11 | Current Ratio | 9.60 | Sales Q/Q | - | Oper. Margin | - | RSI (14) | 52.12 | Volatility | 8.76% 18.92% |
Optionable | No | Debt/Eq | 0.06 | EPS Q/Q | -208.30% | Profit Margin | - | Rel Volume | 0.05 | Prev Close | 2.40 |
Shortable | Yes | LT Debt/Eq | 0.00 | Earnings | Nov 14 BMO | Payout | - | Avg Volume | 1.31M | Price | 2.33 |
Recom | - | SMA20 | 7.47% | SMA50 | 8.16% | SMA200 | -15.41% | Volume | 70,059 | Change | -2.92% |
![]() | ||||||||||||||||||||||||||||||||||||||
![]() | ||||||||||||||||||||||||||||||||||||||
|
||||||||||||||||||||||||||||||||||||||
![]() | ||||||||||||||||||||||||||||||||||||||
bioAffinity Technologies, Inc., a biotechnology company, engages in developing non-invasive diagnostic tests and targeted cancer therapeutics. The company offers CyPath lung, a diagnostic test, for early detection of lung cancer. It also researches targeted therapies to treat cancer at the cellular level. The company was founded in 2014 and is based in San Antonio, Texas. | ||||||||||||||||||||||||||||||||||||||
![]() | ||||||||||||||||||||||||||||||||||||||
![]() |
open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR |
Upgrade your FINVIZ experience
Join thousands of traders who make more informed decisions with our premium features. Real-time quotes, advanced visualizations, backtesting, and much more.
Learn more about FINVIZ*Elite